Bone Therapeutics is a leading cell therapy company addressing high unmet medical needs in the field of orthopaedics and bone diseases.
Bone Therapeutics has a broad, diversified portfolio of bone cell therapy solutions and viscosupplement in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.
Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
Our primary clinical focus is ALLOB ® , an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. In addition, Bone Therapeutics is also developing an enhanced viscosupplement, JTA-004, for the treatment of knee osteoarthritis.
Bone Therapeutics is also conducting preclinical research on next generation products such as combined cell-matrix products for large bone defects and maxillofacial applications.
Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich Intellectual Property estate covering nine patent families.